Can I Take Resveratrol with Vardenafil (Levitra/Staxyn)?

Why This Interaction Matters

Vardenafil (sold as Levitra and the orally disintegrating tablet Staxyn) treats erectile dysfunction by inhibiting phosphodiesterase type 5 (PDE5), which relaxes smooth muscle in penile vasculature and lowers blood pressure systemically [1]. Resveratrol, a polyphenolic stilbene found in red grape skin and commonly sold as a longevity supplement, also lowers blood pressure through nitric oxide (NO) pathway enhancement and mild CYP3A4 inhibition [2].

Two Overlapping Mechanisms

The concern is twofold. First, resveratrol may slow vardenafil clearance by competing for CYP3A4 binding, raising plasma drug concentrations. Second, both compounds push blood pressure downward through overlapping vascular pathways. The combination of higher-than-expected drug levels and additive vasodilation creates a clinically meaningful risk of symptomatic hypotension, particularly in men over 60 or those already on antihypertensives [3].

What the FDA Label Says

The vardenafil prescribing information warns that "potent CYP3A4 inhibitors such as ketoconazole and ritonavir increase vardenafil AUC by 10-fold and 49-fold, respectively" and recommends dose reduction or avoidance [4]. Resveratrol is not a potent inhibitor on the scale of ketoconazole. But the label's principle applies: any substance that slows CYP3A4 activity can shift vardenafil exposure upward.

The CYP3A4 Pharmacokinetic Pathway

Vardenafil undergoes extensive first-pass metabolism. Roughly 80% of its biotransformation runs through CYP3A4, with a smaller contribution from CYP2C9 [4]. This heavy dependence on a single enzyme family makes vardenafil unusually sensitive to CYP3A4 modulation compared to sildenafil, which uses CYP3A4 and CYP2C9 more evenly [5].

How Resveratrol Affects CYP3A4

In vitro data show that trans-resveratrol inhibits CYP3A4 with IC50 values between 1 and 15 micromolar depending on the substrate probe and microsomal model used [6]. A 2010 study in human liver microsomes reported an IC50 of 5.3 micromolar for CYP3A4 inhibition by resveratrol using midazolam as the probe substrate [6]. Whether typical oral supplement doses (250 to 1,500 mg daily) produce portal vein concentrations high enough to reach that IC50 remains uncertain.

Bioavailability Complicates the Picture

Resveratrol has notoriously low oral bioavailability. A pharmacokinetic study in healthy volunteers given 500 mg of oral trans-resveratrol found peak plasma concentrations of only 72.6 ng/mL (0.32 micromolar), well below the in vitro IC50 for CYP3A4 [7]. Portal vein concentrations, however, are higher than systemic plasma levels because resveratrol is absorbed in the gut and delivered to the liver before undergoing extensive glucuronidation. First-pass hepatic exposure could plausibly reach the low micromolar range at supplement doses above 500 mg [7].

This means the interaction risk is dose-dependent. A 100 mg resveratrol capsule is unlikely to cause meaningful CYP3A4 inhibition. A 1,000 mg dose taken with food (which slows gastric transit and increases absorption) raises the probability.

Blood Pressure: The Pharmacodynamic Overlap

Beyond the enzyme pathway, both substances lower blood pressure independently, creating the potential for additive hypotension.

Vardenafil and Blood Pressure

In key trials, vardenafil 10 mg reduced supine systolic blood pressure by a mean of 7 mmHg and diastolic by 8 mmHg at peak plasma concentration [4]. The effect is transient, resolving within 4 to 6 hours, but clinically relevant for men with baseline systolic readings below 110 mmHg.

Resveratrol and Blood Pressure

A 2015 meta-analysis of six randomized controlled trials (N=247) found that resveratrol doses of 150 mg or higher reduced systolic blood pressure by a weighted mean of 11.9 mmHg in participants with baseline systolic readings above 140 mmHg [8]. In normotensive individuals the effect was smaller, averaging 1 to 2 mmHg, which is unlikely to be clinically significant on its own [8].

Combined Risk

The additive scenario is most relevant for men who are hypertensive or on antihypertensive medication. A man taking amlodipine 5 mg (expected systolic reduction of 8 to 10 mmHg), resveratrol 500 mg (potential 3 to 5 mmHg reduction), and then vardenafil 10 mg (7 mmHg reduction) could experience a total systolic drop exceeding 20 mmHg within 1 to 2 hours of the vardenafil dose. Symptoms at that magnitude include dizziness, visual disturbance, and syncope [3].

Resveratrol's Estrogenic Activity: Does It Matter Here?

Resveratrol is classified as a phytoestrogen. It binds estrogen receptor beta (ER-beta) with moderate affinity (Ki approximately 50 nanomolar in competitive binding assays) [9]. This has raised theoretical concerns about whether chronic resveratrol use could affect testosterone-to-estrogen ratios in men.

Clinical Relevance Is Low

A 2014 randomized controlled trial of resveratrol 1,000 mg daily for 45 days in middle-aged men (N=66) found no statistically significant changes in serum total testosterone, free testosterone, estradiol, or sex hormone-binding globulin (SHBG) compared to placebo [10]. The estrogenic binding observed in vitro does not appear to translate into clinically meaningful hormonal shifts at standard supplement doses.

For men taking vardenafil for erectile dysfunction, the concern about resveratrol's estrogenic properties is largely theoretical. No study has linked resveratrol supplementation to worsening erectile function or reduced PDE5 inhibitor efficacy through hormonal mechanisms.

Dose-Separation and Practical Guidance

No regulatory body has issued formal guidance on combining resveratrol with PDE5 inhibitors. The following recommendations are derived from pharmacokinetic principles and the vardenafil FDA label [4].

Timing Strategy

Vardenafil reaches peak plasma concentration (Tmax) in approximately 60 minutes when taken on an empty stomach, or up to 2 hours with a high-fat meal [4]. Its elimination half-life is 4 to 5 hours. Taking resveratrol at least 4 hours before or after vardenafil reduces the window of simultaneous hepatic CYP3A4 competition.

Dose Selection

Start with vardenafil 5 mg if you are adding resveratrol to your regimen (or vice versa). The FDA label recommends a maximum single dose of 5 mg when vardenafil is co-administered with moderate CYP3A4 inhibitors such as erythromycin [4]. While resveratrol is weaker than erythromycin as a CYP3A4 inhibitor, the dose-reduction principle provides a safety margin.

What to Skip

Grapefruit juice is itself a CYP3A4 inhibitor. The American Urological Association notes that "patients taking PDE5 inhibitors should avoid excessive grapefruit juice consumption due to the risk of increased drug exposure" [11]. Combining resveratrol, grapefruit juice, and vardenafil on the same day stacks three CYP3A4 burdens simultaneously. Drop one.

Monitoring If You Take Both

The goal of monitoring is to catch hypotension or unexpected side-effect amplification before it becomes dangerous.

Blood Pressure Checks

Measure seated blood pressure before your first combined use and again 60 to 90 minutes after taking vardenafil. A systolic reading below 90 mmHg or a drop of more than 20 mmHg from baseline warrants discontinuing one of the two agents and contacting your prescriber [3].

Side-Effect Surveillance

Common vardenafil side effects that may intensify with CYP3A4 inhibition include headache (reported in 15% of patients at 10 mg), flushing (11%), nasal congestion (9%), and dyspepsia (4%) [4]. If any of these appear notably worse after adding resveratrol, the interaction is the most likely explanation.

When to Involve Your Prescriber

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states that "patients should disclose all supplements, including resveratrol, to prescribers managing PDE5 inhibitor therapy" [12]. This principle applies regardless of whether the supplement is purchased over the counter. Your prescriber can adjust vardenafil dosing, switch to a PDE5 inhibitor with less CYP3A4 dependence (such as sildenafil or avanafil), or recommend a washout period.

Who Should Avoid This Combination Entirely

Certain clinical profiles tip the risk-benefit ratio against combining resveratrol and vardenafil.

High-Risk Groups

Men taking alpha-blockers (tamsulosin, doxazosin) already carry an elevated hypotension risk with PDE5 inhibitors. Adding resveratrol introduces a third blood-pressure-lowering agent. The vardenafil label states that "in patients taking alpha-blockers, vardenafil should be initiated at 5 mg" [4]. Layering resveratrol on top of this combination is not supported by any safety data.

Men with hepatic impairment (Child-Pugh B or C) metabolize vardenafil more slowly, with AUC increases of 130% to 160% compared to healthy controls [4]. CYP3A4 inhibition from resveratrol would compound this impairment.

Lower-Risk Groups

Healthy men under 65 with normal hepatic function, no antihypertensive medications, and baseline systolic blood pressure above 120 mmHg are at the lowest risk from this combination. For this group, the dose-separation and dose-reduction strategy described above is a reasonable approach, provided they inform their prescriber.

What the Evidence Does Not Yet Tell Us

No randomized controlled trial has directly tested resveratrol plus vardenafil in human subjects. The interaction profile described in this article is extrapolated from in vitro CYP3A4 data, resveratrol pharmacokinetic studies, and the vardenafil FDA label. A 2023 narrative review in the journal Nutrients noted that "the clinical significance of resveratrol's CYP3A4 inhibition remains poorly characterized due to the compound's low systemic bioavailability and rapid conjugation" [13].

Until human interaction data exist, the safest approach is to treat resveratrol as a mild CYP3A4 inhibitor, use the lowest effective vardenafil dose, separate administration times, and monitor blood pressure during initial co-use. Patients taking vardenafil 20 mg (the maximum approved dose) should not add resveratrol without direct physician supervision, as the margin for error at that dose is narrow.